Company News-宜明昂科英文

2023-10-16

ImmuneOnco's clinical trial application for humanized antibody drug IMM47 targeting CD24 was approved by the National Medical Products Administration (NMPA)

On October 16, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the company's independently developed humanized IgG1 CD24 antibody(Project number: IMM47) was approved by the National Medical Products Administration (NMPA) for clinical trials.

2023-09-13

ImmuneOnco published the preclinical research results of IMM47 in the journal "Antibody Therapeutics"

Recently, the R&D team of ImmuneOnco (Hong Kong Stock Exchange stock code: 01541.HK) reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".

2023-09-05

ImmuneOnco Listed on the Main Board of the HKEX

(Hong Kong, September 5th, 2023) ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).

2023-04-07

ImmuneOnco Biopharmaceuticals Named to KPMG China's "2nd Annual Biotechnology Innovation Top 50 Companies List"

On April 7, 2023, KPMG China's "2nd Biotechnology Innovation Top 50" award ceremony was held simultaneously in Beijing, Shanghai and Shenzhen, and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was

2023-03-24

ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China

On March 24, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the patent applications for their independently developed products, IMM47 (CD2